 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
InMode Ltd. (INMD) designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies.
The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions.
InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally.
On November 7th, Inmode (INMD) reported 3rd Quarter September 2019 earnings of $0.42 per share on revenue of $40.0 million. The consensus earnings estimate was $0.29 per share on revenue of $35.5 million. Shares of this recent IPO have formed a bullish "cup and handle formation." Higher share prices are expected for this stock.
Entry Point: $47.00
Stop Loss: $44.50
Trading Range: $13.06 to $58.76
Target Price: $51.70
INMD closed at $53.00
